Literature DB >> 18175247

Maternal obesity and familial history of diabetes have opposing effects on infant birth weight in women with mild glucose intolerance in pregnancy.

Phillip Segal1, Jill K Hamilton, Mathew Sermer, Philip W Connelly, Anthony J G Hanley, Bernard Zinman, Ravi Retnakaran.   

Abstract

OBJECTIVE: Pregnant women with an abnormal screening glucose challenge test (GCT) but without gestational diabetes mellitus (GDM) on subsequent oral glucose tolerance test (OGTT) are at increased risk of delivering macrosomic and large for gestational age (LGA) neonates. We thus sought to evaluate the maternal constitutional and biochemical factors that determine infant birth weight in this patient population.
METHODS: Women with an abnormal GCT were evaluated at the time of their OGTT in late pregnancy. This analysis was restricted to Caucasian women without GDM (N = 86). Maternal demographic and biochemical factors were evaluated in relation to infant birth weight and LGA.
RESULTS: After adjustment for length of gestation, birth weight was positively associated with pre-pregnancy body mass index (BMI) (r = 0.31, p = 0.0063) and negatively correlated with maternal serum levels of the insulin-sensitizing protein adiponectin (r = -0.30, p = 0.0084). On multiple linear regression analysis, pre-pregnancy BMI and weight gain in pregnancy were positive independent determinants of infant birth weight, while family history of diabetes emerged as a negative independent correlate. Logistic regression analysis confirmed that pre-pregnancy BMI was a positive predictor of LGA (odds ratio (OR) = 1.25, 95% confidence interval (CI) 1.05-1.49), whereas family history of diabetes was again identified as a negative determinant (OR = 0.10, 95% CI 0.02-0.59). In contrast, neither measures of glycemia nor insulin resistance/sensitivity were independently associated with birth weight or LGA.
CONCLUSION: In pregnant women with an abnormal GCT but without GDM, pre-gravid maternal obesity predicts increased infant birth weight, whereas family history of diabetes is independently associated with decreased infant size.

Entities:  

Mesh:

Year:  2008        PMID: 18175247     DOI: 10.1080/14767050701827148

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  6 in total

1.  Chronic maternal infusion of full-length adiponectin in pregnant mice down-regulates placental amino acid transporter activity and expression and decreases fetal growth.

Authors:  Fredrick J Rosario; Michael A Schumacher; Jean Jiang; Yoshikatsu Kanai; Theresa L Powell; Thomas Jansson
Journal:  J Physiol       Date:  2012-01-30       Impact factor: 5.182

2.  Intrauterine growth rate in pregnancies complicated by type 1, type 2 and gestational diabetes.

Authors:  E L Lim; T Burden; S M Marshall; J M Davison; M J Blott; J S J Waugh; R Taylor
Journal:  Obstet Med       Date:  2009-03-01

3.  Normalisation of circulating adiponectin levels in obese pregnant mice prevents cardiac dysfunction in adult offspring.

Authors:  Owen R Vaughan; Fredrick J Rosario; Theresa L Powell; Thomas Jansson
Journal:  Int J Obes (Lond)       Date:  2019-05-10       Impact factor: 5.095

4.  Impact of family history of diabetes on blood glucose, lipid levels and perinatal outcomes in pregnant women with gestational diabetes mellitus.

Authors:  Yumei Zhou; Ni Xie; Lixia Zhang; Danqing Chen
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-06-25

5.  An abnormal screening glucose challenge test in pregnancy predicts postpartum metabolic dysfunction, even when the antepartum oral glucose tolerance test is normal.

Authors:  Ravi Retnakaran; Ying Qi; Mathew Sermer; Philip W Connelly; Anthony J G Hanley; Bernard Zinman
Journal:  Clin Endocrinol (Oxf)       Date:  2008-10-21       Impact factor: 3.478

6.  Isolated hyperglycemia at 1 hour on oral glucose tolerance test in pregnancy resembles gestational diabetes mellitus in predicting postpartum metabolic dysfunction.

Authors:  Ravi Retnakaran; Ying Qi; Mathew Sermer; Philip W Connelly; Bernard Zinman; Anthony J G Hanley
Journal:  Diabetes Care       Date:  2008-03-20       Impact factor: 19.112

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.